SUPPORT HOTLINE (888) 901-2226
Donate Now

BRIEF TITLE: Neutron Radiotherapy With Concurrent Checkpoint Inhibitor Immunotherapy (Pembrolizumab) in Patients With Advanced Urothelial Carcinoma

Phase II Trial of Neutron Radiotherapy With Concurrent Checkpoint Inhibitor Immunotherapy (Pembrolizumab) in Patients With Advanced Urothelial Carcinoma


  • Org Study ID: 9940
  • Secondary ID: NCI-2018-00412,9940,P30CA015704,RG3118000
  • NCT ID: NCT03486197
  • NCT Alias:
  • Sponsor: University of Washington - Other
  • Source: University of Washington

Brief Summary

This phase II trial studies how well neutron radiation therapy and pembrolizumab work in treating participants with urothelial carcinoma that has spread to other places in the body. Neutron radiation therapy uses high energy neutrons to kill tumor cells and shrink tumors. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving radiation therapy and pembrolizumab may work better than radiation alone in treating participants with urothelial carcinoma that has spread to other places in the body.

Detailed Description


PRIMARY OBJECTIVES:

I. To assess the overall response rate to neutron radiation (with high relative biological
effectiveness relative to standard photon radiation) to a metastatic focus in combination
with standard of care checkpoint inhibitor immunotherapy (pembrolizumab), in patients with
advanced urothelial carcinoma.

SECONDARY OBJECTIVES:

I. Progression free survival.

II. Overall survival.

III. Safety and tolerability as evaluated by the incidence, severity, duration, causality,
seriousness, and type(s) of adverse events as assessed by Common Terminology Criteria for
Adverse Events (CTCAE) version 4.0

OUTLINE:

Participants receive pembrolizumab intravenously (IV) on days 1 and 22. On day 23,
participants may undergo an optional tumor biopsy and receive 3-5 treatments of neutron
radiation therapy over 2 weeks on days 23-42. Participants receive pembrolizumab IV on day 43
and continue per standard of care in the absence of disease progression or unacceptable
toxicity.

After completion of study treatment, participants are followed up every 3 months.

Overal Status Start Date Phase Study Type
Recruiting January 17, 2019 Phase 2 Interventional

Primary Outcomes:

Primary Outcome 1 - Measure: Overall response rate per immune-modified response evaluation criteria in solid tumors

Primary Outcome 1 - Time Frame: Up to 3 years

Condition:

  • Urothelial Carcinoma

Eligibility

Criteria:
Inclusion Criteria:

- Pathologically proven (either histologic or cytologic) diagnosis of urothelial
carcinoma

- At least two sites of disease that are measurable by Response Evaluation Criteria in
Solid Tumors (RECIST) 1.1 criteria

- Eligible for checkpoint inhibitor immunotherapy (pembrolizumab) per standard of care

- No history of autoimmune disease requiring systemic therapy (e.g. steroids or biologic
agents)

- Absolute neutrophil count (ANC) ≥ 1500 /mcL

- Platelets ≥ 100,000/mcL

- Hemoglobin > 9 g/dL

- Creatinine ≤ 1.5 x upper limit of normal (ULN) OR ≥ 60 mL/min

- Total bilirubin ≤ 1.5 ULN OR direct bilirubin ≤ ULN if total bilirubin > 1.5 x ULN

- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x ULN OR < 5
x ULN if patient has liver metastasis

- Albumin >= 2.5 g/dL

- International normalized ratio (INR) or PT ≤ 1.5 x ULN unless on anticoagulation
therapy, in which case prothrombin time (PT) or partial thromboplastin time (PTT)
should be in the therapeutic range

- PTT ≤ 1.5 x ULN unless on anticoagulation therapy, in which case PT or PTT should be
in the therapeutic range

- Eligible for neutron radiation treatment to 1-3 sites of metastatic disease (lesions
do not have to be symptomatic)

- No steroids for at least 2 weeks prior to enrollment, and patient must not be expected
to require steroids during the study period

- Zubrod performance status 0-2

- Patient must sign study specific informed consent prior to study entry

- Patients who are sexually active must use medically acceptable forms of contraception

- Life expectancy must be > 3 months

Exclusion Criteria:

- Has a known history of active TB (Bacillus tuberculosis)

- Hypersensitivity to pembrolizumab or any of its excipients

- Has a known additional malignancy that is progressing or requires active treatment

- Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent

- Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)

- Has known active hepatitis B (e.g., hepatitis B virus surface antigen [HBsAg]
reactive) or hepatitis C (e.g., hepatitis C virus [HCV] ribonucleic acid [RNA]
[qualitative] is detected)

- Has known psychiatric or substance abuse disorders that would interfere with
cooperation with the requirements of the trial

- Has a history or current evidence of any condition, therapy, or laboratory abnormality
that might confound the results of the trial, interfere with the subject's
participation for the full duration of the trial, or is not in the best interest of
the subject to participate, in the opinion of the treating investigator

- Has known history of, or any evidence of active, non-infectious pneumonitis

- Has an active infection requiring systemic therapy

- Has received a live vaccine within 30 days of planned start of study therapy

- Has known active central nervous system (CNS) metastases and/or carcinomatous
meningitis; subjects with previously treated brain metastases may participate provided
there is no evidence of new or enlarging brain metastases, and are not using steroids
for at least 7 days prior to trial treatment; this exception does not include
carcinomatous meningitis which is excluded regardless of clinical stability
Show More

Gender: All

Minimum Age: 18 Years

Maximum Age: N/A

Healthy Volunteers: No

Official Information

Name: Jing Zeng

Role: Principal Investigator

Affiliation: Fred Hutch/University of Washington Cancer Consortium

Location

Facility Status Contact
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington 98109
United States
Recruiting Jing Zeng
206-598-8822
lathap@uw.edu